Selexis SA and Turgut Pharmaceuticals have entered into a third commercial license agreement that provides Turgut with access to Selexis’ SUREtechnology Platform and SURE CHO-M Cell Line for the development of a high-quality biosimilar product for the treatment of two ultra-rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The new agreement builds on two commercial license agreements established between the companies in July 2016 to develop biosimilar pro...